Treatment
Tocilizumab clinical trials
We’re tracking 57 recruiting studies that include Tocilizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT07108387RecruitingPhase 2
Stopping or reducing tocilizumab for well-controlled giant cell arteritis
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
Atlanta, GeorgiaAges 50 years+ - NCT06654154Recruiting
Vitamin B12 as a marker for disease activity in tocilizumab patients
This study looks at whether vitamin B12 levels in the blood can help tell if your disease is active or if you have an infection while being treated with tocilizumab. The goal is to find a simple way to monitor your condition without extra invasive tests.
Clermont-FerrandAges 18 years+ - NCT06033196RecruitingPhase 2
Tocilizumab to prevent lung transplant rejection
This trial tests a drug called tocilizumab (brand name Actemra) to see if it helps prevent rejection after lung transplantation. Tocilizumab targets part of the immune system that may otherwise attack the new lungs.
Phoenix, ArizonaAges 12–75 - NCT06430736RecruitingPhase 2
Tocilizumab before or during CAR-T therapy
This study tests whether giving tocilizumab (a drug that calms inflammation) before CAR-T cell therapy helps prevent side effects. It compares using it ahead of time versus only when needed. You may be eligible if you are scheduled for CAR-T therapy for lymphoma, leukemia, or myeloma.
Bern, Canton of BernAges 18 years+ - NCT06624436RecruitingPhase 4
Study of anti-inflammatory drugs in brief, controlled inflammation
This study tests how three different anti-inflammatory drugs (dexamethasone, tocilizumab, and anakinra) affect the body's immune response during a controlled, short-term inflammation. It is for healthy young men who can safely receive an experimental substance that temporarily mimics an infection.
Nijmegen, GelderlandAges 18–35 - NCT06927375RecruitingPhase 4
Combination drug therapy for thyroid eye disease
This study tests a combination of two drugs, tocilizumab and flupentixol-melitracen, in people with active, moderate-to-severe thyroid-associated eye disease (TED). It aims to see if this combination can reduce eye bulging, double vision, and anxiety symptoms.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07609940RecruitingPhase 4
Linvoseltamab plus tocilizumab for heavily treated multiple myeloma
This trial tests a combination of two drugs (linvoseltamab and tocilizumab) for adults with multiple myeloma that has stopped responding to standard treatments. Tocilizumab is added to help reduce serious side effects from the main drug.
Los Angeles, CaliforniaAges 18 years+ - NCT05609630RecruitingPhase 3
Testing two medicines for active systemic juvenile arthritis
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
Phoenix, ArizonaAges 1–17 - NCT07006532Recruiting
Tocilizumab for chronic active antibody-mediated rejection
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
TehranAges 18 years+ - NCT07589634RecruitingPhase 2
Tocilizumab to prevent side effects from ramantamig in multiple myeloma
This study tests whether a drug called tocilizumab can prevent serious side effects (cytokine release syndrome) when combined with a new cancer drug called ramantamig. You'll be eligible if you have multiple myeloma that has come back or stopped responding to prior treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT05640271RecruitingPhase 2
Tocilizumab for acute chest syndrome in sickle cell
This trial studies tocilizumab (a medicine that calms inflammation) to treat acute chest syndrome in people with sickle cell disease. It may help improve symptoms and recovery by targeting key immune signals involved in this complication.
Chicago, IllinoisAges 12 years+ - NCT04300686RecruitingPhase 4
Pilot study for severe Takayasu artery inflammation
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
Shanghai, Shanghai MunicipalityAges 14–100 - NCT04691817RecruitingPhase 1/Phase 2
Testing tocilizumab plus atezolizumab after lung cancer treatment failure
This trial studies whether combining tocilizumab with atezolizumab can help people with advanced lung cancer that has already stopped responding to an immune checkpoint medicine. It may help when standard immune therapy (and other treatments) aren’t working anymore.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05067348RecruitingPhase 2
Tocilizumab for generalized myasthenia gravis symptoms
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
Beijing, Beijing MunicipalityAges 18–80 - NCT05845723RecruitingPhase 2
Study drugs for blood-vessel Behçet’s to reduce inflammation
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
Beijing, Beijing MunicipalityAges 18–65 - NCT05846789RecruitingPhase 2
Chemotherapy with or without tocilizumab for breast cancer
This Phase 2 trial tests whether adding tocilizumab (a drug that targets inflammation signals) to standard chemotherapy helps people with triple-negative or ER-low metastatic or locally recurring breast cancer. It’s for adults who have had up to two prior treatments for metastatic disease and who can receive standard chemo.
Atlanta, GeorgiaAges 18 years+ - NCT06016179RecruitingPhase 1
Tocilizumab given through fluid-draining tubes for advanced cancer
This trial tests a drug called tocilizumab, which is given through the tube that drains fluid from your chest or belly. The goal is to see if it can help control cancer-related fluid buildup and improve symptoms.
Pittsburgh, PennsylvaniaAges 18–89 - NCT06297096RecruitingPhase 3
Testing a two-drug combo for lung scarring in scleroderma
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
Warsaw, Masovian VoivodeshipAges 18–74 - NCT06818266RecruitingPhase 3
Tocilizumab for severe chest crisis in sickle cell disease
This trial tests if the drug tocilizumab can help treat acute chest syndrome, a serious lung complication of sickle cell disease. It is for people with sickle cell disease who are hospitalized and need oxygen or breathing support. The study compares tocilizumab to a placebo to see if it speeds up recovery.
ParisAges 2 years+ - NCT06863480RecruitingPhase 1
Trial of tocilizumab for bleeding stroke to prevent later strokes
This trial tests if a drug called tocilizumab (TYENNE) can reduce the risk of delayed strokes after a bleeding stroke from a ruptured aneurysm. It is for adults who had a specific type of brain bleed and need a drain to remove fluid.
Gainesville, FloridaAges 18–89 - NCT07334379RecruitingPhase 2
Tailored treatment for acute breathing problems
This trial tests whether using a blood test to measure inflammation (IL-6) can help doctors decide if you should get either dexamethasone or tocilizumab for COVID-19 or other acute breathing problems. The goal is to find the best treatment faster and reduce side effects.
Toronto, OntarioAges 18 years+ - NCT07377058Recruiting
Tocilizumab study for anti-MDA5 positive dermatomyositis
This trial tests if adding the drug tocilizumab to standard therapy helps people with a rare type of dermatomyositis (anti-MDA5 positive) that often affects the lungs. It compares tocilizumab to a placebo to see if it can improve symptoms and lung function.
Beijing, Beijing MunicipalityAges 18–65 - NCT06381661RecruitingPhase 2
Personalized treatment for sepsis in children and adults
This trial is testing several different treatments to find the best one for each person with sepsis. It looks at specific 'treatable traits' like inflammation, blood clotting problems, or immune system issues to match you with the right therapy. The goal is to improve recovery and survival.
DijonAges 9 months+ - NCT07570173RecruitingPhase 2/Phase 3
MK-1045 for Hard-to-Treat B-Cell Leukemia
This trial tests a new drug called MK-1045 in patients whose acute lymphoblastic leukemia (a blood cancer) has come back or stopped responding to previous treatments. The goal is to see if this drug can help control the cancer when other options haven't worked.
Copenhagen, Capital RegionAges 12 years+
What Tocilizumab is being studied for
Conditions with recruiting Tocilizumab studies.
Common questions
- Are there clinical trials studying Tocilizumab?
- Yes. Clin2 currently lists 57 recruiting studies that include Tocilizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Tocilizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Tocilizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Tocilizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.